StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/309% above fair value
$80.28+3.39 (+4.41%)

Close on Nov 13, 2026Market cap $3.52BP/E –Yield 0.00%

Tarsus Pharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Tarsus Pharmaceuticals's operating margin for the twelve months ending Jun 30, 2026 was -8.0%. For fiscal 2025 it was -15.7%, against -65.9% the year before. The highest annual figure on record is -15.7% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-15.7%+50.2
FY2024Dec 31, 2024-65.9%+754.6
FY2023Dec 31, 2023-820.5%−577.6
FY2022Dec 31, 2022-242.9%−221.6
FY2021Dec 31, 2021-21.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-11.4%+10.2
Q1 FY2026Mar 31, 2026-3.8%+29.8
Q4 FY2025Dec 31, 2025-5.3%+31.5
Q3 FY2025Sep 30, 2025-12.2%+40.1
Q2 FY2025Jun 30, 2025-21.6%+60.0
Q1 FY2025Mar 31, 2025-33.5%+102.9
Q4 FY2024Dec 31, 2024-36.8%+303.2
Q3 FY2024Sep 30, 2024-52.3%+2135.6
Q2 FY2024Jun 30, 2024-81.6%+916.5
Q1 FY2024Mar 31, 2024-136.5%+14.1
Q4 FY2023Dec 31, 2023-339.9%−305.7
Q3 FY2023Sep 30, 2023-2187.9%+1433.8
Q1 FY2023Mar 31, 2023-998.1%+3276.5
Q4 FY2022Dec 31, 2022-150.6%+1115.9
Q2 FY2022Jun 30, 2022-34.2%−67.3
Q1 FY2022Mar 31, 2022-3621.7%−3653.8
Q4 FY2021Dec 31, 2021-4274.6%–
Q3 FY2021Sep 30, 2021-1266.5%–
Q2 FY2021Jun 30, 202133.1%–
Q1 FY2021Mar 31, 202132.0%–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?